124 related articles for article (PubMed ID: 7887241)
1. Results from a phase I clinical trial of HBED.
Grady RW; Salbe AD; Hilgartner MW; Giardina PJ
Adv Exp Med Biol; 1994; 356():351-9. PubMed ID: 7887241
[TBL] [Abstract][Full Text] [Related]
2. HBED: A potential alternative to deferoxamine for iron-chelating therapy.
Bergeron RJ; Wiegand J; Brittenham GM
Blood; 1998 Feb; 91(4):1446-52. PubMed ID: 9454776
[TBL] [Abstract][Full Text] [Related]
3. HBED: the continuing development of a potential alternative to deferoxamine for iron-chelating therapy.
Bergeron RJ; Wiegand J; Brittenham GM
Blood; 1999 Jan; 93(1):370-5. PubMed ID: 9864183
[TBL] [Abstract][Full Text] [Related]
4. Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients.
Boturao-Neto E; Marcopito LF; Zago MA
Braz J Med Biol Res; 2002 Nov; 35(11):1319-28. PubMed ID: 12426631
[TBL] [Abstract][Full Text] [Related]
5. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
[TBL] [Abstract][Full Text] [Related]
6. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia.
Cossu P; Toccafondi C; Vardeu F; Sanna G; Frau F; Lobrano R; Cornacchia G; Nucaro A; Bertolino F; Loi A; De Virgiliis S; Cao A
Eur J Pediatr; 1981 Nov; 137(3):267-71. PubMed ID: 7318837
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Kontoghiorghe CN; Kontoghiorghes GJ
Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
[TBL] [Abstract][Full Text] [Related]
8. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
Kontoghiorghes GJ; Aldouri MA; Hoffbrand AV; Barr J; Wonke B; Kourouclaris T; Sheppard L
Br Med J (Clin Res Ed); 1987 Dec; 295(6612):1509-12. PubMed ID: 3122880
[TBL] [Abstract][Full Text] [Related]
9. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
[TBL] [Abstract][Full Text] [Related]
10. Deferasirox for managing iron overload in people with thalassaemia.
Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831
[TBL] [Abstract][Full Text] [Related]
11. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.
Harmatz P; Grady RW; Dragsten P; Vichinsky E; Giardina P; Madden J; Jeng M; Miller B; Hanson G; Hedlund B
Br J Haematol; 2007 Aug; 138(3):374-81. PubMed ID: 17614825
[TBL] [Abstract][Full Text] [Related]
12. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
13. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
Lai ME; Grady RW; Vacquer S; Pepe A; Carta MP; Bina P; Sau F; Cianciulli P; Maggio A; Galanello R; Farci P
Blood Cells Mol Dis; 2010 Aug; 45(2):136-9. PubMed ID: 20678715
[TBL] [Abstract][Full Text] [Related]
14. Desferrioxamine induced urinary iron excretion in thalassemia.
Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
[TBL] [Abstract][Full Text] [Related]
15. Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience.
Abdelrazik N
Hematology; 2007 Dec; 12(6):577-85. PubMed ID: 17852442
[TBL] [Abstract][Full Text] [Related]
16. Thalassemia.
Cohen AR; Galanello R; Pennell DJ; Cunningham MJ; Vichinsky E
Hematology Am Soc Hematol Educ Program; 2004; ():14-34. PubMed ID: 15561674
[TBL] [Abstract][Full Text] [Related]
17. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
Haghpanah S; Zarei T; Zahedi Z; Karimi M
Hematology; 2014 Jun; 19(4):187-91. PubMed ID: 24074344
[TBL] [Abstract][Full Text] [Related]
18. [Program of hypertransfusion and chelation with desferrioxamine in 10 patients with thalassemia major].
Albo C; Cabrera J; Dios A; Castro M; Ares C; Constenla I; López D
Sangre (Barc); 1995 Dec; 40(6):441-5. PubMed ID: 8850225
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
[TBL] [Abstract][Full Text] [Related]
20. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
